Premenstrual Dysphoric Disorder ( PMDD)Phase 1NCT07818720
MLS101 Study in PMDD
A Phase 1 study testing MLS101 psilocybin in people with Premenstrual Dysphoric Disorder ( PMDD) and PMDD, run by MycoMedica Life Sciences PBC.
Trial summary
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is: Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Premenstrual Dysphoric Disorder ( PMDD), PMDD
- What is being tested?
- MLS101 psilocybin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- No sites listed yet
- Study dates
- Dec 2026to Dec 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Provides informed consent for participating in the study
- Biologically female participants 18-50 years of age (inclusive) at Screening and premenopausal
- Body mass index (BMI) ≥ 18.5 and < 40.0 kg/m2
- Menstrual cycle duration of 24-35 days (inclusive) reported at Screening
- Menstrual cycles are sufficiently regular to allow estimation of menses onset with reasonable accuracy based on participant's reported history and the Investigator's assessment
- Participant has an existing diagnosis of PMDD and history of at least one prior or current medically-supervised treatment for PMDD
Show all 10Show fewer
- CGI-S ≥ 4 for late luteal phase PMDD symptom severity and associated impairment at Screening
- Mean VAS score ≥ 50 on any one of the 4 core symptoms of PMDD at Screening, as measured using the first 4 items on the PMTS-VAS
- Participant is using a medically acceptable form of birth control for at least 8 weeks prior to receiving first dose of study drug and agrees to continue using medically acceptable birth control for at least 4 weeks post last dose in the study. Medically acceptable birth control methods include double-barrier methods used with spermicide, copper or low-dose levonorgestrel-releasing IUD, participant has had tubal ligation, participant is in a monogamous relationship with a vasectomized male or with another female, or participant is celibate as part of her lifestyle and will remain so throughout the study. (Note that for this study, oral, subdermal, transdermal, injectable, and vaginal ring hormonal contraceptives are not allowed).
- If a participant is currently taking SSRI treatment, it must have been maintained as a stable monotherapy for at least 3 months prior to Screening with intent to continue unchanged for the duration of the study.
Who cannot join
- Currently meets DSM-5 criteria for MDD, GAD, Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Borderline Personality Disorder, or Anti-Social Personality Disorder, based on M.I.N.I.
- History of meeting DSM-5 criteria for Major Depressive Episode within the past 6 months from Screening
- History of meeting DSM-5 criteria for Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Anti-Social Personality Disorder, or Borderline Personality Disorder within 24 months from Screening
- History of meeting DSM-5 criteria for Substance or Alcohol Use Disorder in the last 2 years at Screening (Note: mild recreational cannabis use in the judgment of the Investigator, that does not meet criteria for moderate or severe Substance Use Disorder, is not exclusionary)
- Lifetime history of any psychosis or mania not attributable to substance use
- First degree relative with schizophrenia, schizoaffective disorder or bipolar I disorder
Show all 36Show fewer
- Confirmed to be in perimenopause, or diagnosis of Polycystic Ovary Syndrome based on ACOG/Rotterdam criteria, or diagnosis of symptomatic uterine fibroids
- PMDD symptoms attributable to, or exacerbated by, hormonal contraceptives/treatments
- Participant plans to start any new treatment for PMDD, or to stop any ongoing SSRI treatment during the study
- Use of any herbal or supplement with known serotonin-enhancing properties (e.g. St. John's Wort, L-tryptophan, 5-hydroxytryptophan) within the past 3 months at Screening
- Use of any hormonal contraceptive that works primarily by suppression of ovulation, for the past month at Screening. Therefore, use of oral, subdermal, transdermal, injectable, and vaginal ring hormonal contraceptives is excluded. (However, copper IUDs and hormonal IUDs that release low-dose levonorgestrel are acceptable.)
- Use of any non-SSRI antidepressant, antipsychotic, or anticonvulsant within the past 3 months
- Exposure to a neurosteroid, whether marketed or in a clinical trial, during the past 12 months
- Requires ongoing pharmacologic treatment for Attention-deficit/hyperactivity disorder (ADHD)
- Suicidal ideation with intent and plan, suicide attempt, or psychiatric hospitalization during the past 12 months, or an answer of "yes" to Question 4 or 5 on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Use of a classic (serotonergic) psychedelic in any form and at any dose in the past 6 months
- Participation in another psychiatric clinical trial during the past 6 months, or a clinical trial of any other medical intervention during the past 3 months, at Screening
- Estimated glomerular filtration rate (eGFR) below the limit of normal range (< 60 mL/min/1.73m2)
- Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x upper limit of normal (ULN)
- Total bilirubin > 1.5 x ULN (unless the participant has predominantly unconjugated hyperbilirubinemia in the absence of other liver function test [LFT] abnormalities including elevated Direct [conjugated] Bilirubin)
- History or presence of clinically significant cardiovascular disease including valvulopathies, cardiac valve abnormalities; or clinically significant heart murmurs, and/or screening echocardiogram, as determined by the Investigator
- History of or presence of pulmonary hypertension
- Abnormal and clinically significant ECG measurements at Screening (calculated as the average of 3 individual 12-lead ECG measurements) indicating a second- or third- degree atrioventricular block, or one or more of the following:
- QRS ≥ 120 msec
- QTcF > 470 msec
- PR interval > 220 msec
- Known personal or family history of congenital long QT syndrome or sudden death
- Supine resting bradycardia (pulse < 45 bpm) or a supine resting tachycardia (pulse > 100 bpm) at Screening or Day 1
- History of orthostatic hypotension or postural orthostatic tachycardic syndrome, multiple syncopes, or unresolved/ongoing clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness
- History or presence of a neurological or neurodegenerative disorder such Alzheimer's disease or Parkinson's disease, transient ischemic attack, stroke, seizure disorder, or behavioral disturbances resulting from other neurological disorders. (Note: occurrence of childhood febrile seizure is not exclusionary.)
- Any evidence of current or previous clinically significant disease, e.g., clinically relevant hepatic impairment; clinically relevant renal impairment; diabetes mellitus, thyroid disorder (uncontrolled hypo- or hyperthyroidism), or other endocrine disease; cardiovascular disease (e.g., uncontrolled coronary artery disease, uncontrolled hypertension, uncontrolled hypercholesterolemia); uncontrolled gastrointestinal disease (e.g., active peptic ulcer; uncontrolled hematological disease; uncontrolled autoimmune disorders, or other which may impact or confound the results of the study according to the judgment of the Investigator or Sponsor Medical Monitor (MM)
- Any medical condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas], or history of bariatric surgery). History of cholecystectomy ≥ 1 year prior to Screening would be allowable.
- Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- Donation or loss of 500 mL or more of plasma or whole blood within 30 days of Screening
- Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any chronic or acute medical condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational product; or is unable to comply with the study protocol
- -
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is:
- Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD.
Read the detailed description
The purpose of this trial is to investigate the safety and tolerability of intermittent low-dose MLS101 (psilocybin) 2mg, 4mg, and 8mg versus placebo in participants with PMDD. These doses are less than one third of the doses typically administered in high-dose psilocybin studies.
The study will enroll premenopausal women, ages 18-50 (inclusive) with an existing diagnosis of PMDD and history of having tried at least 1 prior treatment for PMDD. There is an initial Screening/Preparation Period of up to 2-5 weeks. The 16-day Treatment Period will span the luteal phase of 1 menstrual cycle. During this time, participants will receive 6 doses of MLS101 capsules in the clinic approximately every 3 days. After the Treatment Period, there is a Follow-up Period of approximately 1 month.
Participants will be monitored after receiving each dose for at least 8 hours in the clinic and must meet specified criteria before discharge. All participants will be escorted home by a companion or via concierge care service after each dosing session.
- Conditions
- Premenstrual Dysphoric Disorder ( PMDD), PMDD
- Being tested
- MLS101 psilocybin, Placebo capsules
- Keywords
- PMDD, PMS, Premenstrual Dysphoric Disorder, psilocybin
- Medical subject headings
- Premenstrual Dysphoric Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MLS101 psilocybinDrug
Patients will be randomized in a 1:1:1:1 ratio to receive 6 doses of either placebo or MLS101 at 2 mg, 4 mg, or 8 mg
Placebo capsulesDrug
Placebo group will receive a total of 6 intermittent doses of placebo
| Study group | Role | What they receive |
|---|---|---|
| Placebo group will receive a total of 6 intermittent doses of placebo | Placebo comparator | Not described Receives: Drug: Placebo capsules |
| MLS101 2 mg group will receive a total of 6 intermittent doses at 2 mg/dose | Active comparator | Not described Receives: Drug: MLS101 psilocybin |
| MLS101 4 mg group will receive a total of 6 intermittent doses at 4 mg/dose | Active comparator | Not described Receives: Drug: MLS101 psilocybin |
| MLS101 8 mg group will receive a total of 6 intermittent doses at 8 mg/dose | Active comparator | Not described Receives: Drug: MLS101 psilocybin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Safety and tolerability of MLS101 and placebo from baseline through Visit 11/Final Telehealth Visit (Day 44 ± 5) as assessed by type, frequency, severity, timing, and relationship to MLS101 of any adverse events (AEs), adverse events of special interest (AESIs) serious adverse events (SAEs)
Measured: From baseline through the final telehealth visit at week 11
Secondary outcomes (10)
No change from baseline to end of study in mitral valve leaflet thickness as measured by transthoracic echocardiogram
Baseline transthoracic echocardiogram to measure mitral valve leaflet thickness. Mitral valve leaflet thickness of < 3 mm is normal, whereas >3 mm in mitral valve leaflet thickness is considered abnormal in an echocardiogram.
Measured: From baseline to week 11
Change in Maximum Plasma Concentreation (Cmax)
Blood samples will be collected at 30 minutes, and 1, 2, 3, 4, 6, and 8 hours after a single dose of study drug to determine the change in Cmax
Measured: Day 1 of treatment only
Change in subjective psychedelic experience from pretreatment to 8 hours after treatment
The Acute Subjective Effects Scale (ASES) is a visual analog scale from 0-10 with 0 being no psychedelic experience and 10 being the most intense. Participants will have to score less than or equal to 2 to be considered recovered from treatment effects.
Measured: From pretreatment to 8 hours after treatment each treatment day
Participant reported drug liking
Drug liking will be assessed using the drug Liking Visual Analog Scale (VAS) which is a scale from 0 which indicates strong dislike to 100 which indicates strong liking and a score of 50 is neutral.
Measured: Once at the end of treatment
No change from baseline in Standardized Field Sobriety Test (SFST)
The SFST will be administered before treatment and 8 hours after treatment. There are 3 sections of the test: Horizontal Gaze Nystagmus (HGN) with a score of 0-6; Walk and Turn (WAT) with a score of 0-8 and One Leg Stand (OLS) with a score of 0-4. In each section, a lower score is passing sobriety. To pass the SFST, a score of equal to or less than 4 is required. To pass the WAT and OLS, a score of equal to or less than 2 is required.
Measured: From baseline pretreatment to 8 hours after treatment
Mini Mental Status Examination (MMSE) to assess general mental status
The MMSE is a scale with a maximum score of 30, with lower score indicating impairment. Participants will be administered the MMSE before treatment and at 8 hours post treatment. Participants must have a score of equal to or greater than 24 to receive treatment, and a score 24-30 AND no more than -3 points worse than pretreatment after 8 hours to be considered unimpaired.
Measured: From pretreatment to 8 hours after treatment.
Change in suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C SSRS)
The CSSRS will be administered prior to treatment on each dosing day, at 8 hours after treatment, and at all follow-up telehealth and in-clinic visits. Participants with C-SSRS ideation score of 4 or 5, or suicidal behavior will not receive treatment. Participants with an acceptable score for treatment will need a score of less than or equal to 3 and no more than 1 point worse than baseline at 8 hours after treatment.
Measured: From pretreatment baseline to 8 hours after treatment and at each telehealth and clinic visits
Change in sleep quality from baseline to end of treatment
The Pittsburgh Sleep Quality Index (PSQI) will be administered at baseline and at end of treatment. This is a subjective assessment of sleep quality. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties.
Measured: From baseline to day 17
Change in subjective psychedelic experience from pretreatment to 8 hours after treatment
The 5-Dimensional Altered States of Consciousness (5D-ASC) scale is a 94-item subjective questionnaire to evaluate the subjective psychedelic experience that rates 11 dimensions from 0-100 with higher scores indicating a more intense subjective psychedelic experience.
Measured: Day 1 of treatment only, prior to treatment to 8 hours after treatment
Change in drug withdrawal symptoms from the day after the last treatment to the final telehealth visit
The Common Drug Withdrawal Symptom Scale - Psilocybin Version (CDWS-Psil) is a subjective scale the evaluates symptoms of drug withdrawal from psilocybin. The scale is comprised of 32 symptoms that the participant rates as no experience (none) a mild experience, a moderate experience and a severe experience.
Measured: From the day after the last study treatment to the final telehealth visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2026
- Study startDec 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Premenstrual Dysphoric Disorder ( PMDD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MycoMedica Life Sciences PBC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07818720
- Sponsor's protocol ID
- MLS101-104
- Status last verified
- Sep 2026
- First submitted
- 25 Aug 2026
- Last updated
- 14 Sep 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)
- ClinicalTrials.gov ID
- NCT07818720
- Acronym / sponsor ID
- MLS101-104
- Conditions
- Premenstrual Dysphoric Disorder ( PMDD), PMDD
- Keywords
- PMDD, PMS, Premenstrual Dysphoric Disorder, psilocybin
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- MycoMedica Life Sciences PBCIndustry (pharma, biotech, devices)
- Study start
- Dec 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 14 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD). The main question it aims to answer is:
- Test the safety and tolerability of the study drug, MLS101 in premenopausal women (ages 18-50 inclusive) with PMDD.
Detailed description
The purpose of this trial is to investigate the safety and tolerability of intermittent low-dose MLS101 (psilocybin) 2mg, 4mg, and 8mg versus placebo in participants with PMDD. These doses are less than one third of the doses typically administered in high-dose psilocybin studies.
The study will enroll premenopausal women, ages 18-50 (inclusive) with an existing diagnosis of PMDD and history of having tried at least 1 prior treatment for PMDD. There is an initial Screening/Preparation Period of up to 2-5 weeks. The 16-day Treatment Period will span the luteal phase of 1 menstrual cycle. During this time, participants will receive 6 doses of MLS101 capsules in the clinic approximately every 3 days. After the Treatment Period, there is a Follow-up Period of approximately 1 month.
Participants will be monitored after receiving each dose for at least 8 hours in the clinic and must meet specified criteria before discharge. All participants will be escorted home by a companion or via concierge care service after each dosing session.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo group will receive a total of 6 intermittent doses of placebo | Placebo comparator | Drug: Placebo capsules |
| MLS101 2 mg group will receive a total of 6 intermittent doses at 2 mg/dose | Active comparator | Drug: MLS101 psilocybin |
| MLS101 4 mg group will receive a total of 6 intermittent doses at 4 mg/dose | Active comparator | Drug: MLS101 psilocybin |
| MLS101 8 mg group will receive a total of 6 intermittent doses at 8 mg/dose | Active comparator | Drug: MLS101 psilocybin |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Provides informed consent for participating in the study
- Biologically female participants 18-50 years of age (inclusive) at Screening and premenopausal
- Body mass index (BMI) ≥ 18.5 and < 40.0 kg/m2
- Menstrual cycle duration of 24-35 days (inclusive) reported at Screening
- Menstrual cycles are sufficiently regular to allow estimation of menses onset with reasonable accuracy based on participant's reported history and the Investigator's assessment
Key exclusion criteria (36 listed)
- Currently meets DSM-5 criteria for MDD, GAD, Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Borderline Personality Disorder, or Anti-Social Personality Disorder, based on M.I.N.I.
- History of meeting DSM-5 criteria for Major Depressive Episode within the past 6 months from Screening
- History of meeting DSM-5 criteria for Panic Disorder, OCD, Anorexia, Bulimia, Binge Eating Disorder, Anti-Social Personality Disorder, or Borderline Personality Disorder within 24 months from Screening
- History of meeting DSM-5 criteria for Substance or Alcohol Use Disorder in the last 2 years at Screening (Note: mild recreational cannabis use in the judgment of the Investigator, that does not meet criteria for moderate or severe Substance Use Disorder, is not exclusionary)
- Lifetime history of any psychosis or mania not attributable to substance use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MLS101 psilocybinPatients will be randomized in a 1:1:1:1 ratio to receive 6 doses of either placebo or MLS101 at 2 mg, 4 mg, or 8 mg | Drug | MLS101 2 mg group will receive a total of 6 intermittent doses at 2 mg/dose, MLS101 4 mg group will receive a total of 6 intermittent doses at 4 mg/dose, MLS101 8 mg group will receive a total of 6 intermittent doses at 8 mg/dose |
| Placebo capsulesPlacebo group will receive a total of 6 intermittent doses of placebo | Drug | Placebo group will receive a total of 6 intermittent doses of placebo |
Primary outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Time frame: From baseline through the final telehealth visit at week 11
Safety and tolerability of MLS101 and placebo from baseline through Visit 11/Final Telehealth Visit (Day 44 ± 5) as assessed by type, frequency, severity, timing, and relationship to MLS101 of any adverse events (AEs), adverse events of special interest (AESIs) serious adverse events (SAEs)
10 secondary outcomes
No change from baseline to end of study in mitral valve leaflet thickness as measured by transthoracic echocardiogram
Time frame: From baseline to week 11
Change in Maximum Plasma Concentreation (Cmax)
Time frame: Day 1 of treatment only
Change in subjective psychedelic experience from pretreatment to 8 hours after treatment
Time frame: From pretreatment to 8 hours after treatment each treatment day
Participant reported drug liking
Time frame: Once at the end of treatment
No change from baseline in Standardized Field Sobriety Test (SFST)
Time frame: From baseline pretreatment to 8 hours after treatment
Mini Mental Status Examination (MMSE) to assess general mental status
Time frame: From pretreatment to 8 hours after treatment.
Change in suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C SSRS)
Time frame: From pretreatment baseline to 8 hours after treatment and at each telehealth and clinic visits
Change in sleep quality from baseline to end of treatment
Time frame: From baseline to day 17
Change in subjective psychedelic experience from pretreatment to 8 hours after treatment
Time frame: Day 1 of treatment only, prior to treatment to 8 hours after treatment
Change in drug withdrawal symptoms from the day after the last treatment to the final telehealth visit
Time frame: From the day after the last study treatment to the final telehealth visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Premenstrual Dysphoric Disorder ( PMDD)
Enrolling by invitation
Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause
Perimenopause, PMDD
RecruitingObservational study
Occupational Physicians Facing Premenstrual Dysphoric Disorder: Knowledge, Perceptions and Practices in Occupational Health
Premenstrual Dysphoric Disorder (PMDD)
Not yet recruitingObservational study
The SPARK-PMDD Study
Premenstrual Dysphoric Disorder, PMDD
RecruitingObservational study
To Establish Whether Individuals With Premenstrual Dysphoric Disorder (PMDD) Demonstrate a Different Luteal-phase Sex Hormone Profile and Ratio Compared With Asymptomatic Controls.
Premenstrual Dysphoric Disorder ( PMDD)
Not yet recruiting
Perimenstrual Symptoms and Emotional Dysregulation in Autism
Autism Spectrum Disorder, Borderline Personality Disorder BPD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing MLS101 psilocybin in people with Premenstrual Dysphoric Disorder ( PMDD) and PMDD, run by MycoMedica Life Sciences PBC.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Executive Director of Clinical Operations ((732) 690-3185, sbasim@mycomedica.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0 (time frame: From baseline through the final telehealth visit at week 11). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026; AzTrials last refreshed its copy on 27 Oct 2026.